levofloxacin   Click here for help

GtoPdb Ligand ID: 10911

Synonyms: DR-3355 | Levaquin® | Quinsair®
Approved drug PDB Ligand
levofloxacin is an approved drug (FDA (1996), EMA (2015))
Compound class: Synthetic organic
Comment: Levofloxacin is a broad-spectrum, third-generation fluoroquinolone antibacterial.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 75.01
Molecular weight 361.14
XLogP 3.7
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CN1CCN(CC1)c1c(F)cc2c3c1OC[C@@H](n3cc(c2=O)C(=O)O)C
Isomeric SMILES CN1CCN(CC1)c1c(F)cc2c3c1OC[C@@H](n3cc(c2=O)C(=O)O)C
InChI InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1
InChI Key GSDSWSVVBLHKDQ-JTQLQIEISA-N
References
1. Bulik CC, Christensen H, Nicolau DP. (2010)
In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance.
Antimicrob Agents Chemother, 54 (1): 557-9. [PMID:19917762]
2. Gellert M, Mizuuchi K, O'Dea MH, Nash HA. (1976)
DNA gyrase: an enzyme that introduces superhelical turns into DNA.
Proc Natl Acad Sci U S A, 73 (11): 3872-6. [PMID:186775]
3. Haas W, Pillar CM, Zurenko GE, Lee JC, Brunner LS, Morris TW. (2009)
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Antimicrob Agents Chemother, 53 (8): 3552-60. [PMID:19506065]
4. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K. (2010)
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Antimicrob Agents Chemother, 54 (5): 1955-64. [PMID:20176911]